Dihexa

Cognitive Enhancement Peptideresearch

Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408

An oligopeptide derived from angiotensin IV that is reported to be 10 million times more potent than BDNF at enhancing cognitive function through hepatocyte growth factor (HGF) signaling.

Overview

Dihexa is a synthetic hexapeptide analog of angiotensin IV developed at Washington State University by Dr. Joseph Harding and colleagues. It was designed to cross the blood-brain barrier and act as a potent hepatocyte growth factor (HGF) agonist in the central nervous system. In animal studies, Dihexa demonstrated extraordinary cognitive-enhancing effects, reversing cognitive deficits in aged rats and facilitating new synapse formation. Its potency is striking — researchers reported it to be approximately 10 million times more potent than BDNF in promoting synaptic connectivity. Dihexa works by binding to HGF and its receptor c-Met, stabilizing the HGF dimer and augmenting its signaling. This promotes dendritic spine formation and synaptogenesis, which are critical processes for learning and memory. Despite exciting preclinical data, Dihexa remains a research compound with no human clinical trials, and its long-term safety profile is unknown.

Mechanism of Action

Dihexa acts primarily through the hepatocyte growth factor (HGF) / c-Met receptor pathway. It: (1) Binds to HGF and stabilizes the active dimer configuration, enhancing HGF signaling; (2) Activates c-Met receptor tyrosine kinase, triggering downstream PI3K/Akt and MAPK/ERK pathways; (3) Promotes dendritic spine formation and synaptogenesis in hippocampal and cortical neurons; (4) Enhances long-term potentiation (LTP), a cellular mechanism underlying learning and memory; (5) Crosses the blood-brain barrier effectively due to its lipophilic hexanoic acid modifications; (6) May promote neuronal survival through anti-apoptotic signaling via HGF/c-Met.

Molecular Formula

C26H42N4O5

Molecular Weight

478.63 g/mol

Sequence

N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide

Dosage Protocols

Dose Range

10mg20mg

Frequency

Once daily

Route

oral (sublingual)

Cycle Length

4-8 weeks

Sublingual administration preferred for better bioavailability. Some users dissolve in DMSO for transdermal application. Highly experimental — no established human dosing.

Source: Community protocols extrapolated from animal studies

Side Effects

EffectSeverity
Headachemild
Elevated blood pressuremoderate
Anxiety or overstimulationmild
Theoretical cancer risksevere

Pros & Cons

Extraordinary potency for cognitive enhancement — 10 million times more potent than BDNF in preclinical models

Crosses the blood-brain barrier effectively, allowing multiple routes of administration

Promotes actual structural brain changes (synaptogenesis) rather than just neurotransmitter modulation

Reversed cognitive deficits in aged animal models, suggesting potential for neurodegenerative conditions

No human clinical trials — all data is from animal studies

HGF/c-Met pathway involvement raises serious concerns about cancer promotion

Long-term safety profile completely unknown

Dosing is entirely experimental with no established human protocols

Research Studies

Legal Status

Not FDA-approved. Available as a research chemical. No specific scheduling in most jurisdictions. Not approved for human use anywhere.

Related Peptides